Delving into the Latest Updates on Hebei People's Hospital with Synapse

Overview

Tags

Neoplasms

Cardiovascular Diseases

Urogenital Diseases

Small molecule drug

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1
Autologous CAR-T	1

Top 5 Target	Count

PSCA(Prostate stem cell antigen)	1
ABCA1(ATP binding cassette subfamily A member 1)	1

This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy of intensive lipid-lowering therapy with a PCSK9 inhibitor plus statin versus statin alone in reversing asymptomatic intracranial atherosclerotic plaques, , assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.

Start Date01 May 2025

Sponsor / Collaborator

Peking Union Medical College Hospital

[+6]

NCT06943729

/ Not yet recruitingNot ApplicableIIT

Clinical Safety and Efficacy of Flow Diverter in the Treatment of Intracranial Aneurysms

To collect the safety and effectiveness data of flow-di in the treatment of intracranial aneurysms in real-world clinical practice, verify its classification of treatment strategies for aneurysms of different locations and shapes, and optimize postoperative medication regimen, provide long-term evidence-based basis for clinical treatment of intracranial aneurysms, and build a database.

Start Date30 Apr 2025

Sponsor / Collaborator

Shanghai Huashan Hospital

[+16]

ChiCTR2500101130

/ SuspendedNot ApplicableIIT

Effect of dexmedetomidine nasal spray on postoperative delirium in elderly patients undergoing hip and knee replacement: a randomized controlled trial

Start Date25 Apr 2025

Sponsor / Collaborator

Hebei People's Hospital

100 Clinical Results associated with Hebei People's Hospital

Login to view more data

0 Patents (Medical) associated with Hebei People's Hospital

Login to view more data

264

Literatures (Medical) associated with Hebei People's Hospital

01 Jun 2025·Molecular Immunology

Neferine reduces synovial inflammation and cardiac complications in a collagen-induced arthritis mouse model via inhibiting NF-κB/NLRP3 inflammasome axis

Article

Author: Cao, Jingjing ; Ni, Yanhui ; Ning, Xiaoran ; Zhang, Huaxing

For the treatment of rheumatoid arthritis (RA), there are limited options for drugs with fewer side effects. Neferine possesses anti-inflammatory, anti-fibrotic, and cardioprotective properties, but its effectiveness in the treatment of RA remains unclear. Our study aimed to explore the impact of neferine administration on ankle joint inflammation and cardiac complications of collagen-induced arthritis (CIA) mice. The CIA model was introduced in male DBA/1 mice via subcutaneous injection of Type II collagen (CII) into the tail. We found that neferine alleviated ankle joint inflammation, cartilage erosion, and bone destruction, as well as reduced the levels of IL-6, TNF-α, IL-1β, and IL-18 in the serum of CIA mice. Furthermore, neferine reduced the expression of synovial damage markers (RANKL, MMP-3, and MMP-13) in the ankle joints of CIA mice. Mechanistically, neferine lowered the levels of NF-κB pathway-related molecules such as p-IκBα, p-p65, and nuclear p65 in the synovial tissue of CIA mice. Simultaneously, neferine reversed the upregulation of NLRP3, ASC, and cleaved-caspase-1 levels in the synovial tissue of CIA mice. Additionally, our results showed that neferine reduced the contents of myocardial injury markers (cTnI, CK-MB, and LDH), alleviated myocardial fibrosis, decreased expression of α-SMA and Collagen I, as well as mitigated the activation of fibrosis-related TGF-β/Smad signaling. In summary, our study demonstrates that neferine attenuates chondral and synovial inflammation in a CIA mouse model by inhibiting the activation of the NF-κB/NLRP3 inflammasome, and neferine has a protective effect on the hearts of CIA mice.

01 May 2025·Heart

Gaps in knowledge and management of iron deficiency in heart failure: a nationwide survey of cardiologists in China

Article

Author: Liu, Wanjun ; Chen, Zhiping ; Sun, Di ; Zheng, Zhaoqi ; Bai, Ming ; Li, Peizhao ; Wang, Xi ; Su, Lina ; Liu, Yujian ; Meng, Zhen ; Cao, Hong-Shuai ; Liu, Jiang ; Liu, Chuanfen ; Ren, Jingyi ; Gong, Jingjing ; Zhou, Ying ; Zhao, Xuecheng ; Zhang, Hu ; Zheng, Jingang ; Su, Guangsheng ; Zhang, Hao ; Su, Xiaoling ; Zhang, Yanqing ; Maimaiti, Ailifeire ; Feng, Lina ; Sun, Lijie ; Lai, Jinsheng ; Lamu, Gusang ; Liu, Wenjie ; Li, Zeng ; Hu, Dan ; Li, Sufang ; Wu, Manyan ; Zhou, Pei ; Cleland, John G F ; An, Hui ; Xu, Bihe ; Cao, Lulei ; Lu, Zhan ; Chen, Sizhen ; Hao, Xiang ; Kang, Naidan

BackgroundHeart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, for those with ID, intravenous iron if the left ventricular ejection fraction is <50%. Guideline adherence to these recommendations by cardiologists in China is unknown.Methods and resultsAn independent academic web-based survey was designed and distributed via social networks to cardiologists across China. Overall, 1342 cardiologists (median age 34 years, IQR 30–39, 51% women) from all provinces of China completed this survey. More than half were unaware of the need to screen for ID in HF and did not do so routinely in their clinical practice. Approximately 80% were not familiar with the diagnostic criteria for ID in HF guidelines, and only 0.8% recognised transferrin saturation <20% as an independent marker of ID. Regarding iron repletion, only 14% preferred intravenous to oral iron for correcting ID compared with 68% favouring oral iron. Three-quarters were unfamiliar with methods for calculating intravenous iron dose. Furthermore, over 80% were unaware that current guidelines only recommend ferric carboxymaltose or ferric derisomaltose for correcting ID. The main barriers to using intravenous iron were lack of knowledge and experience. Despite such poor awareness and practice, most cardiologists were interested in learning more about managing ID in HF.ConclusionsIn this nationwide survey of cardiologists in China, we identified large gaps in both knowledge and management of ID. This survey will help guide the development of educational programmes to improve care for patients with HF and ID in China.

04 Apr 2025·Medicine

A case report of anti-AMPAR encephalitis with involuntary limb shaking and aphasia

Article

Author: Xing, Jiahao ; Huo, Tiantian ; Geng, Minxia ; Wang, Tianjun ; Li, Shuang

Rationale:Anti-alpha-amino-3-hydroxy-5-methyl-4-isozolipropionic acid receptor (AMPAR) encephalitis is a rare autoimmune encephalitis mediated by anti-AMPAR antibodies produced on the surface of neuronal cells. Anti-AMPAR encephalitis has a variety of clinical manifestations, the common clinical manifestations are characterized by borderline encephalitis, including short-term memory loss, confusion, behavioral abnormalities, and seizures.Patient concerns:Here we report a case of anti-AMPAR encephalitis in an adolescent female with aphasia as the first symptom of involuntary limb shaking.Diagnoses:The diagnosis of anti-AMPAR encephalitis is based on clinical symptoms and further detection of serum antibodies.Interventions and outcomes:The patient responded well to intravenous methylprednisolone combined with immunoglobulin treatment, and her limbs no longer shook and her speech was fluent.Lessons:Early diagnosis of autoimmune encephalitis is challenging due to the heterogeneity of clinical manifestations. Our patient was initially diagnosed with involuntary limb movement, so we should conduct further research on symptoms associated with autoimmune encephalitis.

100 Deals associated with Hebei People's Hospital

Login to view more data

100 Translational Medicine associated with Hebei People's Hospital

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 2 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anti-PSCA CAR-T (Hebei People's Hospital) ( PSCA )	Castration-Resistant Prostatic Cancer More	Phase 2 Clinical
CN115521272 ( ABCA1 )	Atherosclerosis More	Discovery
Regulatory T cell exosomes(Zhide Medical Laboratory/Hebei People's Hospital/Beijing Chao-Yang Hospital)	Age Related Macular Degeneration More	Suspended